Welcome to LookChem.com Sign In|Join Free

CAS

  • or

289906-10-1

Post Buying Request

289906-10-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

289906-10-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 289906-10-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,9,9,0 and 6 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 289906-10:
(8*2)+(7*8)+(6*9)+(5*9)+(4*0)+(3*6)+(2*1)+(1*0)=191
191 % 10 = 1
So 289906-10-1 is a valid CAS Registry Number.

289906-10-1Relevant articles and documents

Identification of new Cdc25 dual specificity phosphatase inhibitors in a targeted small molecule array

Ducruet, Alexander P.,Rice, Robert L.,Tamura, Kenji,Yokokawa, Fumiaki,Yokokawa, Shiho,Wipf, Peter,Lazo, John S.

, p. 1451 - 1466 (2007/10/03)

Dual specificity protein phosphatases (DSPases) are key regulators of signal transduction, oncogenesis and the cell cycle. Few potent or specific inhibitors of DSPases, however, are readily available for these pharmacological targets. We have used a combinatorial/parallel synthetic approach to rigidify the variable core region and modify the side chains of 4-(benzyl-(2-[2,5-diphenyl-oxazole-4-carbonyl)-amino]-ethyl)-carbamoyl)-2-decanoylamino butyric acid (or SC-ααδ9), which is the most active element in a previously described library of phosphatase inhibitors (Rice, R. L.; Rusnak, J. M.; Yokokawa, F.; Yokokawa, S.; Messner, D. J.; Boynton, A. L.; Wipf, P.; Lazo, J. S. Biochemistry 1997, 36, 15965). Several analogues were identified as effective inhibitors of the protein tyrosine phosphatase (PTPase) PTP1B and the DSPases VHR and Cdc25B2. Two compounds, FY3-αα09 and FY21-αα09, were partial competitive inhibitors of Cdc25B2 with K(i) values of 7.6±0.5 and 1.6±0.2 μM, respectively. FY21-αα09 possessed only moderate activity against PTP1B. Consistent with its in vitro anti-phosphatase activity, FY21-αα09 inhibited growth in MDA-MB-231 and MCF-7 human breast cancer cell lines. FY21-αα09 also inhibited the G2/M transition in tsFT210 cells, consistent with Cdc25B inhibition. Several architectural requirements for DSPase inhibition were revealed through modification of the side chain moieties or variable core region of the pharmacophore, which resulted in decreased compound potency. The structure of FY21-αα09 provides a useful platform from which additional potent and more highly selective phosphatase inhibitors might be generated. Copyright (C) 2000 Elsevier Science Ltd.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 289906-10-1